利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.017 秒)

    Method and device for photodynamic therapy
    2.
    发明授权
    Method and device for photodynamic therapy 有权
    光动力疗法的方法和装置

    公开(公告)号：US08454991B2

    公开(公告)日：2013-06-04

    申请号：US12302812

    申请日：2007-07-17

    申请人： Thomas Woo ,  Gerald George Miller ,  Ragupathy Madiyalakan

    发明人： Thomas Woo ,  Gerald George Miller ,  Ragupathy Madiyalakan

    IPC分类号： A61F13/00 ,  A61K9/70

    CPC分类号： C09K11/07 ,  A61K8/355 ,  A61K8/415 ,  A61K41/0057 ,  A61K2800/434 ,  A61N5/062 ,  A61N2005/0645 ,  A61N2005/0651 ,  A61Q9/04 ,  A61Q19/08

    摘要： The present invention relates to a photodynamic therapy method and uses thereof for treating an individual in need thereof, comprising administering a photosensitizer to an individual and activating the photosensitizer with a chemiluminescent light source, and/or a light-emitting diode light source, wherein the light source is in dermal contact with the individual. The present invention also relates to a device for photodynamic therapy comprising a permeable reservoir, for containing a photosensitizer formulation for skin application, the device is adapted to deliver the photosensitizer to the individual. The present invention also relates to a device for photodynamic therapy, comprising a permeable reservoir for containing a photosensitizer formulation for skin application and a light source. The light source is a chemiluminescent light source or a light-emitting diode light source and the device is adapted to deliver the photosensitizer to the individual and to irradiate a part of an individual to activate the photosensitizer.

    摘要翻译： 本发明涉及一种光动力治疗方法及其用途，用于治疗有需要的个体，包括向个体施用光敏剂并用化学发光光源和/或发光二极管光源激活光敏剂，其中， 光源与个体真皮接触。 本发明还涉及一种用于光动力学治疗的装置，其包括可渗透储存器，用于容纳用于皮肤应用的光敏剂配方，所述装置适于将光敏剂递送给个体。 本发明还涉及一种用于光动力治疗的装置，其包括用于容纳用于皮肤应用的光敏剂配方和光源的可渗透储存器。 光源是化学发光光源或发光二极管光源，并且该装置适于将光敏剂递送给个体并照射个体的一部分以激活光敏剂。

    MUC16 MONOCLONAL ANTIBODY AND USES THEREOF
    4.
    发明申请
    MUC16 MONOCLONAL ANTIBODY AND USES THEREOF 有权

    公开(公告)号：US20210101994A1

    公开(公告)日：2021-04-08

    申请号：US17048119

    申请日：2019-04-30

    申请人： QUEST PHARMATECH INC.

    发明人： Ragupathy Madiyalakan ,  Michael Hollingsworth ,  Prakash Radhakrishnan

    IPC分类号： C07K16/30

    摘要： The present document describes an antibody or an antigen-binding fragment that bind to O-glycan mucin-type glycoprotein MUC16 comprising three variable heavy domain complementarity determining regions (CDR)(CDR H1, H2 and H3), and three variable lighy domain CDR (CDR L1, L2 and L3). The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of inhibiting tumor growth of a tumor expressing O-glycan mucin-type glycoprotein MUC16.

    Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of disease
    5.
    发明授权
    Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of disease 有权
    改善治疗性IgE抗体生物活性以治疗疾病的方法

    公开(公告)号：US08945566B2

    公开(公告)日：2015-02-03

    申请号：US13456492

    申请日：2012-04-26

    申请人： Birgit C. Schultes ,  Christopher F. Nicodemus

    发明人： Birgit C. Schultes ,  Christopher F. Nicodemus

    IPC分类号： A61K39/395 ,  A61K39/00

    CPC分类号： A61K39/0011 ,  A61K39/395 ,  A61K2039/555 ,  C07K2317/52 ,  Y10S424/805 ,  Y10S530/862 ,  A61K2300/00

    摘要： The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.

    摘要翻译： 本发明提供了一种用于增加本发明的治疗性IgE抗体在患者治疗中的生物活性（例如生物安全性和功效）的方法。 本发明的方法包括：i）向患者施用治疗性IgE抗体与至少一种生物活性增强剂的组合，ii）用于给药和施用本发明的治疗性IgE抗体的策略治疗方案和方案，以及iii ）使用治疗性IgE抗体，其具有包含至少一个特异性结合抗原表位的抗原结合区的可变区，其中所述表位不是高度重复的或不重复的。

    Polymeric nanoparticles for photosensitizers
    6.
    发明授权
    Polymeric nanoparticles for photosensitizers 有权
    用于光敏剂的聚合物纳米颗粒

    公开(公告)号：US08916205B2

    公开(公告)日：2014-12-23

    申请号：US14236212

    申请日：2011-08-11

    申请人： Azita Haddadi ,  Ragupathy Madiyalakan ,  Thomas Woo

    发明人： Azita Haddadi ,  Ragupathy Madiyalakan ,  Thomas Woo

    IPC分类号： A61K9/14 ,  C07C49/84 ,  A61K41/00 ,  A61K9/06 ,  A61K9/00 ,  A61K9/51

    CPC分类号： A61K41/0057 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/5153 ,  A61K31/122 ,  C07C49/84 ,  Y10S977/773

    摘要： Biodegradable polymeric nanoparticles comprising an inner core formed of a photodynamic agent capable of being activated to generate cytotoxic singlet oxygen are prepared. These nanoparticles have anti-cell proliferation activity and are useful in treating both cancerous and non-cancerous conditions including actinic keratosis, psoriasis and acne vulgaris. Preferably, the photodynamic agent is a hypocrellin B derivative while the polymeric nanoparticle comprises polyglycolic acid, polylactic acid or poly(lactide-co-glycolide). Hypocrellin-comprising nanoparticles are demonstrated to be activated by light or hydrogen peroxide.

    摘要翻译： 制备包含由能够活化以产生细胞毒性单线态氧的光动力剂形成的内核的可生物降解的聚合物纳米粒子。 这些纳米颗粒具有抗细胞增殖活性，并且可用于治疗癌和非癌症状况，包括光化性角化病，牛皮癣和寻常型痤疮。 优选地，光动力剂是低聚物B衍生物，而聚合物纳米颗粒包含聚乙醇酸，聚乳酸或聚（丙交酯 - 共 - 乙交酯）。 证明含有hypocrellin的纳米颗粒被光或过氧化氢活化。

    POLYMERIC NANOPARTICLES FOR PHOTOSENSITIZERS
    7.
    发明申请
    POLYMERIC NANOPARTICLES FOR PHOTOSENSITIZERS 有权
    用于光敏剂的聚合纳米粒子

    公开(公告)号：US20140170229A1

    公开(公告)日：2014-06-19

    申请号：US14236212

    申请日：2011-08-11

    申请人： Azita Haddadi ,  Ragupathy Madiyalakan ,  Thomas Woo

    发明人： Azita Haddadi ,  Ragupathy Madiyalakan ,  Thomas Woo

    IPC分类号： A61K41/00

    CPC分类号： A61K41/0057 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/5153 ,  A61K31/122 ,  C07C49/84 ,  Y10S977/773

    摘要： Biodegradable polymeric nanoparticles comprising an inner core formed of a photodynamic agent capable of being activated to generate cytotoxic singlet oxygen are prepared. These nanoparticles have anti-cell proliferation activity and are useful in treating both cancerous and non-cancerous conditions including actinic keratosis, psoriasis and acne vulgaris. Preferably, the photodynamic agent is a hypocrellin B derivative while the polymeric nanoparticle comprises polyglycolic acid, polylactic acid or poly(lactide-co-glycolide). Hypocrellin-comprising nanoparticles are demonstrated to be activated by light or hydrogen peroxide.

    摘要翻译： 制备包含由能够活化以产生细胞毒性单线态氧的光动力剂形成的内核的可生物降解的聚合物纳米粒子。 这些纳米颗粒具有抗细胞增殖活性，并且可用于治疗癌和非癌症状况，包括光化性角化病，牛皮癣和寻常型痤疮。 优选地，光动力剂是低聚物B衍生物，而聚合物纳米颗粒包含聚乙醇酸，聚乳酸或聚（丙交酯 - 共 - 乙交酯）。 证明含有hypocrellin的纳米颗粒被光或过氧化氢活化。

    Rapamycin peptides conjugates: synthesis and uses thereof
    8.
    发明授权
    Rapamycin peptides conjugates: synthesis and uses thereof 有权
    雷帕霉素肽缀合物：其合成及其应用

    公开(公告)号：US07659244B2

    公开(公告)日：2010-02-09

    申请号：US10578105

    申请日：2004-11-03

    申请人： Sanjay K. Sharma ,  Thomas Woo ,  Selvaraj Naicker

    发明人： Sanjay K. Sharma ,  Thomas Woo ,  Selvaraj Naicker

    IPC分类号： A61K38/12 ,  C07K7/50

    CPC分类号： C07D498/18 ,  A61K38/00 ,  A61L31/16 ,  A61L2300/416 ,  C07K5/0812 ,  C07K5/1016 ,  C07K7/06

    摘要： The present invention relates to new rapamycin derivatives for the inhibition of cell proliferation. The compounds can advantageously target two proteins in dividing cells and interfere with cell cycle. There is thus provided derivatives of rapamycin in which the 42 position of rapamycin is linked to an amino acid or a peptide through a carbamate ester linkage. These rapamycin derivatives can be synthesized by reacting 42-O-(4-Nitrophenoxycarbonyl) rapamycin and an amino acid or a free amino peptide under basic conditions. These rapamycin derivatives can be used to inhibit the cell cycle and are therefore useful for treating cell proliferation disorders.

    摘要翻译： 本发明涉及用于抑制细胞增殖的新雷帕霉素衍生物。 该化合物可有利地靶向分裂细胞中的两种蛋白质并干扰细胞周期。 因此提供了雷帕霉素的衍生物，其中雷帕霉素的42位通过氨基甲酸酯键与氨基酸或肽连接。 这些雷帕霉素衍生物可以通过在基本条件下使42-O-（4-硝基苯氧羰基）雷帕霉素和氨基酸或游离氨基肽反应来合成。 这些雷帕霉素衍生物可用于抑制细胞周期，因此可用于治疗细胞增殖障碍。

    Combination therapy for treating disease
    10.
    发明授权
    Combination therapy for treating disease 有权
    联合治疗疾病

    公开(公告)号：US08038994B2

    公开(公告)日：2011-10-18

    申请号：US10831886

    申请日：2004-04-26

    申请人： Birgit C. Schultes ,  Christopher F. Nicodemus ,  Antoine A. Noujaim ,  Ragupathy Madiyalakan

    发明人： Birgit C. Schultes ,  Christopher F. Nicodemus ,  Antoine A. Noujaim ,  Ragupathy Madiyalakan

    IPC分类号： A61K39/395

    CPC分类号： C07K16/3069 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2300/00

    摘要： Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.

    摘要翻译： 公开了用于治疗癌症的方法，包括向患有癌症的患者施用异型抗体和化学治疗药物。 还公开了一种诱导患者中存在于宿主血清中的多表位体内肿瘤抗原的宿主免疫应答的方法，该抗原不引起有效的宿主免疫应答，其包括向患者施用化学治疗药物和 组合物，其包含特异性结合抗原上的第一表位并使结合剂形成结合剂/抗原对的结合剂，其中针对抗原上的第二表位引起有效的宿主免疫应答。